Kerendia(finerenone)
Kerendia (finerenone) is a small molecule pharmaceutical. Finerenone was first approved as Kerendia on 2021-07-09. It has been approved in Europe to treat chronic renal insufficiency and type 2 diabetes mellitus. It is known to target mineralocorticoid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Kerendia
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| kerendia | New Drug Application | 2022-09-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FINERENONE, KERENDIA, BAYER HLTHCARE | |||
| 2026-07-09 | NCE | ||
| 2025-09-01 | M-279 | ||
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 8 | 8 | 4 | 9 | 30 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | 5 | 6 | 3 | 8 | 23 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 7 | 2 | 3 | 7 | 19 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 5 | 3 | 2 | 6 | 16 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | 6 | — | 6 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | 2 | 1 | 1 | 4 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 1 | — | 2 | — | 3 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | 1 | 1 | 2 |
| Albuminuria | D000419 | EFO_0004285 | R80.9 | — | 1 | — | 1 | — | 2 |
| Diabetes complications | D048909 | — | — | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | 3 | 3 | 4 | — | 2 | 12 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | 1 | 3 | 2 | — | 1 | 7 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | 2 | — | 1 | 3 |
| Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | — | 1 | — | 1 | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Left ventricular dysfunction | D018487 | — | — | — | 2 | — | — | — | 2 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | — | 2 | 2 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | — | 2 | 2 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 1 | 1 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Finerenone |
| INN | finerenone |
| Description | Finerenone, sold under the brand name Kerendia, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA). It is taken orally (swallowed by mouth).
|
| Classification | Small molecule |
| Drug class | aldosterone antagonists (spironolactone type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2 |
Identifiers
| PDB | — |
| CAS-ID | 1050477-31-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2181927 |
| ChEBI ID | — |
| PubChem CID | 60150535 |
| DrugBank | DB16165 |
| UNII ID | DE2O63YV8R (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NR3C2
NR3C2
Organism
Homo sapiens
Gene name
NR3C2
Gene synonyms
MCR, MLR
NCBI Gene ID
Protein name
mineralocorticoid receptor
Protein synonyms
aldosterone receptor, mineralocorticoid receptor 1, mineralocorticoid receptor 2, mineralocorticoid receptor delta, Nuclear receptor subfamily 3 group C member 2
Uniprot ID
Mouse ortholog
Nr3c2 (110784)
mineralocorticoid receptor (Q8VII9)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,471 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,021 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use